Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Alan Lau"'
Autor:
J. Carl Barrett, Lei Zhao, Amanda G. Paulovich, Richard G. Ivey, Zena Wilson, Antonio Ramos-Montoya, Martine P. Roudier, Jeffrey R. Whiteaker, Gareth Hughes, Alan Lau, Claire Rooney, Elaine Cadogan, Rajesh Odedra, Andrew J. Pierce, William J. Howat, Lucy H. Young, Elizabeth A. Harrington, Nicola Griffin, Antonio Garcia-Trinidad, Gemma N Jones
Publikováno v:
British Journal of Cancer
Background AZD0156 and AZD6738 are potent and selective inhibitors of ataxia-telangiectasia-kinase (ATM) and ataxia-telangiectasia-mutated and Rad3-related (ATR), respectively, important sensors/signallers of DNA damage. Methods We used multiplexed t
Autor:
Philip J. Jewsbury, Rajesh Odedra, Alan Lau, Sylvie Guichard, James W.T. Yates, Kevin Blades, Gary Wilkinson, Kevin Michael Foote, Dan Heathcote, Turner Paul, Christine M. Wood, J. Willem M. Nissink, Zena Wilson, Thomas M. McGuire
Publikováno v:
Journal of Medicinal Chemistry. 61:9889-9907
The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DN
Autor:
Alan Lau, Frances M. Richards, Christopher J. Minteer, Sandra Bernaldo de Quirós Fernández, Timothy Isaac Johnson, Duncan I. Jodrell, Daniel Kottmann, Charles R. Dunlop, Yann Wallez, Larissa S. Carnevalli
Publikováno v:
EBioMedicine
EBioMedicine, Vol 68, Iss, Pp 103396-(2021)
EBioMedicine, Vol 68, Iss, Pp 103396-(2021)
BackgroundChemotherapy and targeted agent anti-cancer efficacy is largely dependent on the proliferative state of tumours, as exemplified by agents that target DNA synthesis/replication or mitosis. As a result, cell cycle specificities of a number of
Autor:
Neil H. James, Alan Lau, Antonio Ramos-Montoya, Gemma N Jones, Giuditta Illuzzi, Paul W. G. Wijnhoven, Katarzyna Falenta, Rebecca L. Lloyd, Lucy H. Young, Zena Wilson, Jonathan Stott, Emma Dean, Christophe D. Chabbert
Publikováno v:
Oncogene
The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib is FDA approved for the treatment of BRCA-mutated breast, ovarian and pancreatic cancers. Olaparib inhibits PARP1/2 enzymatic activity and traps PARP1 on DNA at single-strand breaks, leading
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2baf3724e07bec854228e122b048829f
https://www.repository.cam.ac.uk/handle/1810/322860
https://www.repository.cam.ac.uk/handle/1810/322860
Autor:
James W.T. Yates, Yann Wallez, Charles R. Dunlop, Frances M. Richards, Chiara Fornari, Siang-Boon Koh, Timothy Isaac Johnson, Duncan I. Jodrell, Alan Lau, Sandra Bernaldo de Quirós Fernández
Publikováno v:
Molecular Cancer Therapeutics. 17:1670-1682
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers, and overall survival rates have barely improved over the past five decades. The antimetabolite gemcitabine remains part of the standard of care but shows very limited antitumor e
Autor:
Alan Lau, Ahrum Min, Kyung Hun Lee, Miso Lee, Do Youn Oh, Mark J. O'Connor, Seongyeong Kim, Debora Keunyoung Kim, Tae Yong Kim, Jin Won Kim, Hee Jun Kim, Hyemin Jang, Jeffrey L. Brown, Yaewon Yang, Yung-Jue Bang, Seock-Ah Im
Publikováno v:
Molecular Cancer Therapeutics. 16:566-577
Ataxia telangiectasia and Rad3-related (ATR) can be considered an attractive target for cancer treatment due to its deleterious effect on cancer cells harboring a homologous recombination defect. The aim of this study was to investigate the potential
Autor:
Jeffrey L. Brown, Jung-Eun Kim, Hee Jun Kim, Mark J. O'Connor, Alan Lau, Tae Yong Kim, Seock-Ah Im, Seongyeong Kim, Yaewon Yang, Yung-Jue Bang, Ahrum Min, Kyung Hun Lee, Hyemin Jang, Do Youn Oh, Miso Lee
Publikováno v:
International Journal of Cancer. 140:109-119
Ataxia telangiectasia and Rad3-related (ATR) proteins are sensors of DNA damage, which induces homologous recombination (HR)-dependent repair. ATR is a master regulator of DNA damage repair (DDR), signaling to control DNA replication, DNA repair and
Autor:
Niall M. B. Martin, Bastiaan Evers, Charlotte Knights, Janneke E. Jaspers, Jos Jonkers, Attilla Ting, Henry Brown, Keith W. Caldecott, Sven Rottenberg, Rajesh Odedra, Lenka Oplustil O'Connor, Robert Hugh Bradbury, Aaron Cranston, David Alan Rudge, Mark J. O'Connor, Marina Pajic, Louise J. Jones, Alan Lau, Stuart L. Rulten
Publikováno v:
Cancer Research. 76:6084-6094
The PARP inhibitor AZD2461 was developed as a next-generation agent following olaparib, the first PARP inhibitor approved for cancer therapy. In BRCA1-deficient mouse models, olaparib resistance predominantly involves overexpression of P-glycoprotein
Autor:
Sébastien L. Degorce, Steven C. Glossop, Alan Lau, Elaine Cadogan, Barlaam Bernard Christophe, Richard Ducray, Kurt Gordon Pike, Andrew G. Thomason, Gilles Ouvry, Allan Dishington, Franck Lach, Lorraine A. Hassall, Thomas M. McGuire, Thorsten Nowak
Publikováno v:
Journal of Medicinal Chemistry. 59:6281-6292
A novel series of 3-quinoline carboxamides has been discovered and optimized as selective inhibitors of the ataxia telangiectasia mutated (ATM) kinase. From a modestly potent HTS hit (4), we identified molecules such as 6-[6-(methoxymethyl)-3-pyridin
Autor:
Jon Read, Kevin Michael Foote, Johannes Wilhelmus Maria Nissink, Alan Lau, Louise Goodwin, Lisa Wissler, Jason Breed, Benjamin Taylor, Nichola L. Davies, Husam Alwan, James S. Scott, Jason Grant Kettle, Kay Eckersley, D.R Jones, Michal Bista, Marta Wylot, Graeme Walker, Shaun M. Fillery, Helena Käck
Publikováno v:
Journal of Medicinal Chemistry. 59:2346-2361
Recent literature has claimed that inhibition of the enzyme MTH1 can eradicate cancer. MTH1 is one of the "housekeeping" enzymes that are responsible for hydrolyzing damaged nucleotides in cells and thus prevent them from being incorporated into DNA.